Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, start as another MPN, like polycythemia vera (PV) or essential thrombocythemia (ET), and later evolve into myelofibrosis.

Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
View More
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cecilia BrownMyelofibrosis | August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Cecilia BrownMyeloproliferative Neoplasms | June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownMyeloproliferative Neoplasms | June 16, 2023
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Cecilia BrownMeeting News | June 15, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Keightley AmenMyelofibrosis | June 11, 2023
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Keightley AmenMyelofibrosis | June 8, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Cecilia BrownMeeting News | June 7, 2023
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Prithviraj Bose, MDMyelofibrosis | June 7, 2023
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
Keightley AmenMyelofibrosis | June 7, 2023
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
Keightley AmenMyelofibrosis | June 6, 2023
Researchers followed the patients for three years after their final dose of luspatercept.
Keightley AmenMyelofibrosis | June 5, 2023
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Cecilia BrownMyelofibrosis | June 5, 2023
Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts.
Keightley AmenMyelofibrosis | June 5, 2023
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
Cecilia BrownMyelofibrosis | June 3, 2023
The pooled analysis set included patients from both arms of the intent-to-treat populations in SIMPLIFY-1 and SIMPLIFY-2.
Cecilia BrownMyelofibrosis | June 1, 2023
The trial will enroll certain patients who had an "inadequate response” to ruxolitinib alone.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
Dr. Tefferi discusses risk stratification systems for primary myelofibrosis, transplant considerations, and more.
Cecilia BrownMyelofibrosis | May 15, 2023
They detected mutated TP53 in 49 (13%) patients, with 30 of those patients showing a multihit configuration.
Cecilia BrownMyelofibrosis | May 11, 2023
The model was developed and validated using data from the CIBMTR and EBMT registries.
Cecilia BrownMyelofibrosis | May 10, 2023
The study evaluated longitudinal symptom score changes to “complement the interpretation of the landmark symptom ...
Cecilia BrownMeeting News | April 19, 2023
Planning for a phase III trial of the combination is underway.
Leah SherwoodMeeting News | April 19, 2023
Jan Bewersdorf, MD, discusses a current ongoing phase I study investigating the combination of ruxolitinib and abemaciclib.
Cecilia BrownMyelofibrosis | March 21, 2023
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
Cecilia BrownMyelofibrosis | March 16, 2023
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Cecilia BrownMyelofibrosis | February 8, 2023
The study’s investigators are continuing to monitor overall survival and conduct ongoing patient follow-up.
Cecilia BrownMyelofibrosis | January 24, 2023
The overall risk of death from primary myelofibrosis declined by more than 50% after the U.S. FDA approved ruxolitinib.
Kerri FitzgeraldMeeting News | December 19, 2022
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Leah SherwoodMeeting News | December 13, 2022
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
Keightley AmenMeeting News | December 12, 2022
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Keightley AmenMyelofibrosis | December 10, 2022
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
Keightley AmenMyelofibrosis | December 10, 2022
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
Keightley AmenMeeting News | December 10, 2022
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Kerri FitzgeraldMyelofibrosis | December 10, 2022
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Kerri FitzgeraldMyelofibrosis | December 10, 2022
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Keightley AmenMyeloproliferative Neoplasms | December 9, 2022
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
Cecilia BrownMyelofibrosis | December 7, 2022
Findings from a new study “underscore the limited therapeutic value of luspatercept” in anemia and myelofibrosis.
Leah SherwoodMyelofibrosis | November 29, 2022
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
Cecilia BrownMyelofibrosis | November 16, 2022
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
Latest News

September 22, 2023